- Posts: 1127
- Thank you received: 276
!!! DISCUSSION GROUP RULES !!!
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
New articles posted here - update 6-28-17
- Rob16
- Offline
I just reread the 11-5 article on CD8+ T cell........ and noticed the mention of Vitamin D as a mediator of T cells and potentially being helpful with autoimmune diseases. Are there any patients here who have mentioned Vitamin D as helping with their counts? How about with SLE (Ellen might be headed in that direction)?
Please Log in or Create an account to join the conversation.
- eklein
- Offline
- Posts: 1353
- Thank you received: 167
Erica
And she was!
Diagnosed May 2005, lowest count 8K.
4/22/08: 43K (2nd Rituxan)
10/01/09: 246K, 1/8/10: 111K, 5/21/10: 233K
Latest count: 7/27/2015: 194K
Please Log in or Create an account to join the conversation.
- Ann
- Offline
- Posts: 1895
- Thank you received: 355
Rob16 wrote: I just reread the 11-5 article on CD8+ T cell........ and noticed the mention of Vitamin D as a mediator of T cells and potentially being helpful with autoimmune diseases. Are there any patients here who have mentioned Vitamin D as helping with their counts? How about with SLE (Ellen might be headed in that direction)?
I don't know if vitamin D has helped with my counts but my haematologist has started checking everyone's vitamin D levels regularly. Mine was low and I got it back to normal range with supplements but I couldn't say if it helped stabilise my counts.. who knows?
Please Log in or Create an account to join the conversation.
- Winnifred
- Offline
- Posts: 784
- Thank you received: 125
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
www.jmedicalcasereports.com/content/7/1/91
Case report
Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports
Abstract
Introduction
Immune thrombocytopenic purpura is thought to be characterized by an immune response against the host’s own platelets. If the thrombocytopenia is severe, patients are initially treated with high-dose steroids. Other more toxic second line treatments are considered if steroids fail. Here, we report the case of two patients in whom conventional treatment was unsuccessful but who responded to hydroxychloroquine and high-dose vitamin D replacement therapy. To the best of our knowledge, this is the first description of successful treatment for immune thrombocytopenia with high-dose vitamin D and hydroxychloroquine.
....
Conclusions
In our two case reports, we found an association between vitamin D deficiency and immune thrombocytopenia where platelet levels responded to vitamin D treatment and hydroxychloroquine but not to prednisone. We believe there may be synergism between vitamin D supplementation and hydroxychloroquine. The mechanism by which high-dose vitamin D results in increased platelet counts in immune thrombocytopenia patients is unknown. However, vitamin D has long been thought to play an immunomodulatory role, which may include a dampened immune response in patients with immune thrombocytopenia or other autoimmune diseases.
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
Erica, do you think you may have read about problems with SLE and sunlight (which I have read about) and remembered it incorrectly as Vitamin D? If you were correct, I would appreciate any citations you can find, as Ellen is about to become a Vitamin D guinea pig!I don't have citations available, but there has been some buzz that vitamin D could be problematic for some immune disorders like SLE.
Erica
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
www.news-medical.net/news/2009/04/09/48189.aspx
Excuse me for saying so, but Erica wouldn't confuse sunlight and Vitamin D! Too much intelligence in that head of hers!
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
I have a long history with low Vitamin D and have taken high dose prescription D for a few years. The OTC supplements didn't do anything for me and it took 14 months of 50,000 IU's a week to get me to a normal level. Have Ellen's levels been tested? You should do that before starting it so you have a baseline.
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
onlinelibrary.wiley.com/doi/10.1002/ajh.23609/abstract
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Abstract:
Treatment of patients with lupus-associated thrombocytopenia (SLE-ITP) is not standardized. We report data on efficacy and safety of hydroxychloroquine (HCQ) in this setting and in ITP patients with positive antinuclear antibodies (ANA) without definite SLE. Inclusion criteria were: definite diagnosis of ITP with a platelet count (PLT) <50 × 109/L, ANA ≥ 1/160 on Hep2 cells with or without a definite diagnosis of SLE, and no sustained response to at least one previous treatment-line and treatment with HCQ. Response criteria were Complete Response (CR) for PLT ≥ 100 × 109/L and Response (R) for PLT ≥30 × 109/L and at least twice the initial value. Forty patients (32 females) with a mean age of 35 ± 17 years and PLT at ITP diagnosis of 14 ± 13 × 109/L were analyzed. Twelve (30%) patients had a SLE-ITP, 28 patients had only positive ANA. All the patients failed to respond to oral prednisone with a median of two treatment-lines (1–5) before HCQ which was initially given in combination with another ITP treatment in 36 patients. Overall response rate was 60% (24/40) including 18 lasting CR and six lasting R maintained with a median follow-up of 64 months (6–146), in ¾ of cases with only HCQ and no concomitant ITP treatment. The response rate (CR+R) was higher in the SLE group vs ANA-positive group (83% vs 50%, P < 0.05). No patient stopped HCQ because of a side-effect. HCQ appears to be a safe and effective second line treatment for patients with SLE-ITP or ITP and high titer of ANA. This trial was registered at www.clinicaltrials.gov as # NCT01549184. Am. J. Hematol., 2013. © 2013 Wiley Periodicals, Inc
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
Good advice on getting a Vitamin D baseline before starting supplements.
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
You are so right about Erica!No, Erica is referring to this:
www.news-medical.net/news/2009/04/09/48189.aspx
Excuse me for saying so, but Erica wouldn't confuse sunlight and Vitamin D! Too much intelligence in that head of hers!
That article you cited looks kinda iffy, though. I followed the link back to autoimmunityresearch.org/
and found an organization far outside the mainstream. Not much into peer review!
Sometimes the kooks are proven right, though!
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Please Log in or Create an account to join the conversation.
- eklein
- Offline
- Posts: 1353
- Thank you received: 167
I've not had mine checked but I'm a good candidate to have low levels, I avoid sun far more than most - I have a new project in Honolulu (yes!) and I walk around with a big hat, long sleeves and even long gloves. I get hives from just a few minutes of exposure. Lucky for me Hawaii is lovely in the evening and at night. And I have an indoor job.
If I can remember I'm going to ask my dr. to check my D levels. Interested to see what you report Rob.
Erica
And she was!
Diagnosed May 2005, lowest count 8K.
4/22/08: 43K (2nd Rituxan)
10/01/09: 246K, 1/8/10: 111K, 5/21/10: 233K
Latest count: 7/27/2015: 194K
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Methods: Combination of standard-dose rituximab (weekly x 4) and usually 3 4-day cycles of 28mg/m2 (max. 40mg) dex at 2-week intervals (R+3Dex) was explored in 67 pediatric and adult pts with ITP at WCMC. Patients were monitored with CBCs obtained weekly and then at less frequent intervals if a response was achieved. Best response (after 8 weeks to avoid transient effects of dex) was determined. Patients were categorized as CR (platelet count≥100x109/L) or PR (50-100x109/L). Relapse was defined as either two consecutive platelet counts <50x109/L and/or need for additional therapy. The duration of response was calculated from date of first rituximab administration to relapse or latest follow-up as of July 31st 2013.
Results: Overall, 50 of 67 pts treated with R+3Dex achieved a best response of either a CR (n=43) or a PR (n=7) at 8 weeks or later from start of therapy for an overall response rate of 75%. Seventy-three percent of pts received R+3Dex; variations were primarily in the timing and amount of dex given. Fifteen responders, 9 CRs and 6 PRs, relapsed at a median of 9 months. Seventy percent of the responders (or 52% of all pts treated) maintain a continuous response with platelet counts ≥ 50 x 109/L as of their last visit at a median f/u of 20 months. Kaplan Meier Analysis estimates 44% of all pts treated (Figure) and 59% of responders (Figure) maintained a best response without relapse at 67 months after initiating treatment. If only those with ITP ≤ 24 months are included, the estimated long term response rate is 59% (p=0.0017) versus only 19% for those with a duration of ITP > 24 months (Figure). Of 36 responding children and adults who had ITP ≤ 24 months, 29 continued to respond as of last follow up. Adults initially responded better than children (p=0.0019) but the long-term responses were not different (Figure). Pts achieving a CR had longer response than those achieving a PR.
Adverse events related to R+Dex were usually mild-moderate, although 3 pts had serum sickness and 2 had transient colitis. IgG levels fell to below the lower limit of normal for age in 14 of 67 pts, 10 of whom had their IgG levels return to normal. In 6 of 14, IgG levels were < 400 mg/dl, some of whom received IVIG. Fifteen patients had serial BK/JC levels without ever detecting virus.
Conclusions: R+3Dex provides clearly superior results to rituximab alone. Notably, there was a 75% response rate overall (50/67 pts) compared to 50% with R alone. The 5 year response rate was almost 50% of all patients and 3/5 of responders. In patients who had had ITP for ≤ 2 years, the response is comparable to what has been reported with splenectomy. Specifically the results in the ≤ 2 year group suggest that R+3Dex is an effective way to induce indefinitely normal platelet counts in pts with a “short” duration of ITP. R+3Dex was tolerable although patients had difficulty with 3 cycles of dex. The 21% rate of hypogammaglobulinemia, higher than that seen with R alone, is also evidence of the mechanism of R+3Dex affecting both B cells and plasma cells. The lasting, long-lived, unmaintained responses observed in this study suggest that this combination therapeutic strategy should be further tested in a controlled trial in patients with newly diagnosed, persistent, and early chronic ITP, whether or not they have been previously treated with other agents.
ash.confex.com/ash/2013/webprogram/Paper62543.html
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Please Log in or Create an account to join the conversation.
- Ann
- Offline
- Posts: 1895
- Thank you received: 355
I did comment that I found it a bit worrying that it was something totally unexpected and wonder what other unexpected effects might appear later on!
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
I always wonder why it jump starts remission. A valid reason would be nice at some point.
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
A combination of bortezomib and rituximab yields a dramatic response in a woman with highly
refractory immune thrombocytopenic purpura: a case report
Abstract
Introduction
Chronic refractory immune thrombocytopenic purpura can be a challenging condition to treat. By definition, the standard first and second line treatments have failed in these patients and modalities such as thrombopoiesis-stimulating agents and more intensive immunosuppressive drugs are therefore used. However, there still remains a subset of patients who continue to be refractory to treatment.
Case presentation
We present the case of a 30-year-old Hispanic woman with recurrent intracranial bleeds, in whom multiple lines of treatment had failed. She was treated with a combination of bortezomib and rituximab based on previously published data that suggested this therapy effectively blocks all antibody-producing cells. Our patient’s platelet counts rapidly improved and subsequently normalized following this treatment.
Conclusion
To the best of our knowledge, this case represents the first report of the effective use of
bortezomib and rituximab in highly refractory immune thrombocytopenic purpura. We believe further study of this therapy is warranted in this setting.
www.jmedicalcasereports.com/content/pdf/1752-1947-8-19.pdf
Bortezomib is a proteasome inhibitor used for treating relapsed multiple myeloma and mantle cell lymphoma. It is marketed as Velcade by Millennium Pharmaceuticals and Cytomib by Venus Remedies.
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, Xu RR, Guo CS, Wang XM, Cheng YF, Ni H, Hou M.
Author information
Abstract
BACKGROUND:
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder, in which platelet GPIIb/IIIa and GPIb/IX are the two most frequently targeted autoantigens. Our previous studies in animal models of ITP demonstrated that intravenous immunoglubin G (IVIG) could protect against anti-GPIIb/IIIa-mediated thrombocytopenia but failed to ameliorate ITP induced by most anti-GPIb/IX antibodies.
OBJECTIVES:
The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.
PATIENTS/METHODS:
In this retrospective study, a cohort of 156 previously untreated adults with severe ITP who underwent IVIG therapy (0.4g/kg/day for 5 days) was analyzed. The primary outcome was response defined as platelet counts ≥ 30 × 109 /L and doubling of baseline counts within 7 days of dosing, and absence of bleeding.
RESULTS AND CONCLUSIONS:
Among the 66 patients with anti-GPIb/IX antibodies, only 24 (36.4%) achieved a response, as compared with 72 of 90 patients (80.0%) who were negative for anti-GPIb/IX antibodies (relative risk 2.2, 95% confidence interval 1.6-3.1). This study found no difference in response between patients with autoantibodies to GPIIb/IIIa (61.7%) and those without anti-GPIIb/IIIa antibodies (61.3%). Logistic regressions, including main effects and the interaction between these two antibodies, showed no influence of anti-GPIIb/IIIa antibodies on the effects of anti-GPIb/IX antibodies with regards to their association with IVIG response. Thus, in adults with ITP, the presence of anti-GPIb/IX autoantibodies is a predictive factor for poor response to IVIG treatment. Trial registration: ClinicalTrials.gov NCT01666795. This article is protected by copyright. All rights reserved.
www.ncbi.nlm.nih.gov/pubmed/24517219
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
Abstract
Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy. However, when eltrombopag is discontinued, platelet counts usually return to baseline within 2 weeks. Here, we describe the clinical characteristics of the, to the best of our knowledge, largest case series of patients with ITP, who presented sustained responses after discontinuing eltrombopag (n = 12). The median time from diagnosis to eltrombopag initiation was 24 months (range, 1-480). The median number of prior therapies was 5 (range, 1-7), and the median duration of eltrombopag treatment was 5 months (range, 1-13). Three patients received eltrombopag for only 1 month. The treatment was well-tolerated. The median (range) follow-up of this case series was of 7 months (6-20), during which all patients maintained a safe platelet count without the need for anti-ITP treatment. The communication of such cases may support the conduction of new studies to investigate which predictive factors could identify ITP patients with sustained responses after discontinuing eltrombopag without additional therapy. The need of long-term use of eltrombopag should be re-examined.
www.ncbi.nlm.nih.gov/pubmed/24499036
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
www.ncbi.nlm.nih.gov/pubmed/24617442
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
We found that platelets in ITP patients exist in an activated state. In patients who are responsive to steroids, the treatment reverses this situation.
Steroids are also used in the treatment of recurring migraines. I have never heard explained why they are effective, but this study may hold the answer. One theory of migraines involves the aggregation of platelets, so deactivating the platelets would lessen platelet aggregation and prevent migraines . It would be interesting to see this same study done on migraine patients.
This might also explain why ITP patients sometimes exhibit bruising even though their CBC shows adequate platelet levels; if they are taking steroids the steroids may be interfering with clotting. Also, this might explain why patients with Cushing's Disease/Syndrome are prone to bruising: excessive cortisol may be blocking the ability of their platelets to clot.
Does anyone have a clue why steroids increase platelet counts?
Please Log in or Create an account to join the conversation.
- Ashegh
- Offline
- Posts: 5
- Thank you received: 1
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
The theory is that steroids suppress antibody production which in turn causes less platelet destruction. Sort of the same reason they work for allergies....suppress the immune system and stop the overreaction to external factors.
Please Log in or Create an account to join the conversation.
- Rob16
- Offline
- Posts: 1127
- Thank you received: 276
Please Log in or Create an account to join the conversation.
- Ann
- Offline
- Posts: 1895
- Thank you received: 355
I don't have time to look it up as I have to go to work but it'll all be on google somewhere.
Please Log in or Create an account to join the conversation.
- Sandi
- Topic Author
- Offline
- Sandi Forum Moderator Diagnosed in 1998, currently in remission. Diagnosed with Lupus in 2006. Last Count - 344k - 6-9-18
- Posts: 12436
- Thank you received: 2377
I never really researched exactly how Prednisone works, but I do know that it suppresses antibodies for many autoimmune disorders. As far as illnesses, there are other parts of the immune system that work too...spleen, lymph nodes, thymus, white cells, etc....
Please Log in or Create an account to join the conversation.
Stay Informed
IMPORTANT!
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.
Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org
© Copyright 1997 - 2024, Platelet Disorder Support Association. All rights reserved.
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.